The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Gueth Anton since 2009.
This trader's CIK number is 1274940.
At the time of last reporting, Gueth Anton was the Director of Antares Pharma, Inc.. (stock ticker symbol ATRS).
Also see all insider trading activities at Antares Pharma, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2021 | ATRS | 0 | $0 | 100,000 | $429,000 | 40,000 | $66,400 |
| 2016 | ATRS | 50,000 | $36,000 | 0 | $0 | 0 | $0 |
| 2014 | ATRS | 5,000 | $10,000 | 0 | $0 | 0 | $0 |
| 2013 | ATRS | 0 | $0 | 150,000 | $632,299 | 0 | $0 |
| 2012 | ATRS | 0 | $0 | 87,500 | $249,462 | 492,594 | $629,206 |
| 2010 | ATRS | 8,000 | $11,280 | 0 | $0 | 0 | $0 |
| 2009 | ATRS | 1,000 | $600 | 0 | $0 | 0 | $0 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2021-07-08 | ATRS | Sale | 100,000 | 4.29 | 429,000 |
| 2021-05-04 | ATRS | Option Ex | 40,000 | 1.66 | 66,400 |
| 2016-03-18 | ATRS | Buy | 50,000 | .72 | 36,000 |
| 2014-08-11 | ATRS | Buy | 5,000 | 2.00 | 10,000 |
| 2013-09-03 | ATRS | Sale | 25,000 | 4.42 | 110,575 |
| 2013-08-01 | ATRS | Sale | 25,000 | 4.41 | 110,349 |
| 2013-07-01 | ATRS | Sale | 25,000 | 4.15 | 103,675 |
| 2013-07-01 | ATRS | Sale | 25,000 | 4.15 | 103,675 |
| 2013-07-01 | ATRS | Sale | 25,000 | 4.15 | 103,675 |
| 2013-06-03 | ATRS | Sale | 25,000 | 4.01 | 100,350 |
| 2012-05-29 | AIS | Option Ex | 33,000 | 1.09 | 35,871 |
| 2012-05-29 | AIS | Option Ex | 459,594 | 1.29 | 593,335 |
| 2012-05-30 | AIS | Sale | 87,500 | 2.85 | 249,462 |
| 2010-09-27 | AIS | Buy | 8,000 | 1.41 | 11,280 |
| 2009-05-15 | AIS | Buy | 1,000 | .60 | 600 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Gueth Anton (Director of Antares Pharma, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.